Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
3
50%
Ph phase_4
1
17%
Ph phase_2
1
17%
Ph not_applicable
1
17%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
3(50.0%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (16.7%)
Phase 33 (50.0%)
Phase 41 (16.7%)
N/A1 (16.7%)

Trials by Status

completed467%
terminated117%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

NCT06054815
completedphase_3

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

NCT03061214
completedphase_3

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

NCT00976937
completedphase_4

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

NCT01744236
terminatedphase_3

Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

NCT01834274
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06054815Phase 2

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

Completed
NCT03061214Phase 3

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

Completed
NCT00976937Phase 3

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

Completed
NCT01744236Phase 4

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

Completed
NCT01834274Phase 3

Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

Terminated
NCT01751321Not Applicable

Glucose Variability With DPP-4 Inhibition

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6